Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus)

Gene Therapy

Volumn 19, Issue 1, 2012, Pages 109-113

  Alba, R ^a   Bradshaw, A C ^a   Mestre Frances N ^b   Verdier, J M ^b   Henaff, D ^c   Baker, A H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b University of Montpellier   (France)

^c INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

Author keywords

FX binding ablated Ad5 vectors; gene delivery; in vivo biodistribution; liver detargeting; non human primates

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 10; HEXON PROTEIN; PROTEOHEPARAN SULFATE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOACCUMULATION; CELL MEMBRANE; CONTROLLED STUDY; GENE DELIVERY SYSTEM; GENETIC TRANSDUCTION; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; LIVER; LIVER CELL; LIVER CELL MEMBRANE; MACROPHAGE; MICROCEBUS MURINUS; MOUSE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PROTEIN BINDING; RODENT; SPLEEN;

ADENOVIRIDAE; ANIMALS; CELL MEMBRANE; CHEIROGALEIDAE; FACTOR X; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GENOME, VIRAL; HEPARAN SULFATE PROTEOGLYCANS; HEPATOCYTES; IMMUNOHISTOCHEMISTRY; LIVER; PROTEIN BINDING; SPLEEN;

HUMAN ADENOVIRUS TYPE 5; MICROCEBUS MURINUS; PRIMATES; RODENTIA;

EID: 84855452437     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.87     Document Type: Article

References (29)

1. Jaffe HA, Danel C, Longenecker G, Metzger M, Setoguchi Y, Rosenfeld MA et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1992; 1: 372-378.
2. Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001; 3: 28-35. (Pubitemid 32509802)
3. Schnell MA, Zhang Y, Tazelaar J, Gao GP, Yu QC, Qian R et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001; 3: 708-722. (Pubitemid 32509868)
4. Koizumi N, Kawabata K, Sakurai F, Watanabe Y, Hayakawa T, Mizuguchi H. Modified adenoviral vectors ablated for coxsackievirus-adenovirus receptor, alphav integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. Hum Gene Ther 2006; 17: 264-279.
5. Mizuguchi H, Koizumi N, Hosono T, Ishii-Watabe A, Uchida E, Utoguchi N et al. Car-or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Therapy 2002; 9: 769-776. (Pubitemid 34679304)
6. Nicklin S, Wu E, Nemerow G, Baker A. The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther 2005; 12: 384-393. (Pubitemid 41150124)
7. Alba R, Bradshaw AC, Parker AL, Bhella D, Waddington SN, Nicklin SA et al. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 2009; 114: 965-971.
8. Parker AL, Waddington SN, Nicol CG, Shayakhmetov DM, Buckley SM, Denby L et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 2006; 108: 2554-2561.
9. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 2005; 79: 7478-7491. (Pubitemid 40756784)
10. Vigant F, Descamps D, Jullienne B, Esselin S, Connault E, Opolon P et al. Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther 2008; 16: 1474-1480.
11. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397-409. (Pubitemid 351200513)
12. Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, Stewart PL et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 2008; 105: 5483-5488. (Pubitemid 351753889)
13. Alba R, Bradshaw AC, Coughlan L, Denby L, McDonald RA, Waddington SN et al. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 2010; 116: 2656-2664.
14. Bradshaw AC, Parker AL, Duffy MR, Coughlan L, van Rooijen N, Kähäri VM et al. Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathog 2010; 6: e1001142.
15. Lievens J, Snoeys J, Vekemans K, Van Linthout S, de Zanger R, Collen D et al. The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer. Gene Therapy 2004; 11: 1523-1531. (Pubitemid 39359460)
16. Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson III A, Galanis E et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 1498-1504. (Pubitemid 46594102)
17. Morral N, O'Neal WK, Rice K, Leland MM, Piedra PA, Aguilar-Córdova E et al. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther 2002; 13: 143-154. (Pubitemid 34075178)
18. Ni S, Bernt K, Gaggar A, Li ZY, Kiem HP, Lieber A. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum Gene Ther 2005; 16: 664-677. (Pubitemid 40864267)
19. Smith TA, Idamakanti N, Marshall-Neff J, Rollence ML, Wright P, Kaloss M et al. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum Gene Ther 2003; 14: 1595-1604. (Pubitemid 37452870)
20. Raper SE, Haskal ZJ, Ye X, Pugh C, Furth EE, Gao GP et al. Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses. Hum Gene Ther 1998; 9: 671-679. (Pubitemid 28200623)
21. Brunetti-Pierri N, Stapleton GE, Palmer DJ, Zuo Y, Mane VP, Finegold MJ et al. Pseudohydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. Mol Ther 2007; 15: 732-740. (Pubitemid 46431993)
22. Fontanellas A, Hervás-Stubbs S, Mauleón I, Dubrot J, Mancheño U, Collantes M et al. Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates. Mol Ther 2010; 18: 754-765.
23. Sullivan DE, Dash S, Du H, Hiramatsu N, Aydin F, Kolls J et al. Liver-directed gene transfer in non-human primates. Hum Gene Ther 1997; 8: 1195-1206. (Pubitemid 27394128)
24. Sakurai F, Nakamura S, Akitomo K, Shibata H, Terao K, Kawabata K et al. Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates. Mol Ther 2008; 16: 726-733. (Pubitemid 351426174)
25. Nunes FA, Furth EE, Wilson JM, Raper SE. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum Gene Ther 1999; 10: 2515-2526. (Pubitemid 29489725)
26. Schuettrumpf J, Zou J, Zhang Y, Schlachterman A, Liu YL, Edmonson S et al. The inhibitory effects of anticoagulation on in vivo gene transfer by adeno-associated viral or adenoviral vectors. Mol Ther 2006; 13: 88-97. (Pubitemid 41763486)
27. Wisse E, Jacobs F, Topal B, Frederik P, De Geest B. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Therapy 2008; 15: 1193-1199.
28. Nicol CG, Graham D, Miller WH, White SJ, Smith TA, Nicklin SA et al. Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther 2004; 10: 343-353.
29. Seiradake E, Henaff D, Wodrich H, Billet O, Perreau M, Hippert C et al. The cell adhesion molecule 'CAR' and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog 2009; 5: e1000277.